{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361699993440329216.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1038/ncponc1187"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/ncponc1187.pdf"}},{"identifier":{"@type":"URI","@value":"https://www.nature.com/articles/ncponc1187"}}],"dc:title":[{"@value":"Strategies for discovering novel cancer biomarkers through utilization of emerging technologies"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381699993440329216","@type":"Researcher","foaf:name":[{"@value":"Vathany Kulasingam"}]},{"@id":"https://cir.nii.ac.jp/crid/1381699993440329217","@type":"Researcher","foaf:name":[{"@value":"Eleftherios P Diamandis"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"17434254"},{"@type":"EISSN","@value":"17434262"}],"prism:publicationName":[{"@value":"Nature Clinical Practice Oncology"}],"dc:publisher":[{"@value":"Springer Science and Business Media LLC"}],"prism:publicationDate":"2008-08-12","prism:volume":"5","prism:number":"10","prism:startingPage":"588","prism:endingPage":"599"},"reviewed":"false","dc:rights":["https://www.springer.com/tdm","https://www.springer.com/tdm"],"url":[{"@id":"https://www.nature.com/articles/ncponc1187.pdf"},{"@id":"https://www.nature.com/articles/ncponc1187"}],"createdAt":"2008-08-12","modifiedAt":"2022-04-16","relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360004231242216320","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Identification of vitronectin as a novel serum marker for early breast cancer detection using a new proteomic approach"}]},{"@id":"https://cir.nii.ac.jp/crid/1360005519565207168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comparison of Claudin 18.2 expression in primary tumors and lymph node metastases in Japanese patients with gastric adenocarcinoma"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706236308736","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Identification of a high molecular weight kininogen fragment as a marker for early gastric cancer by serum proteome analysis"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848658412094720","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Promoter-level transcriptome in primary lesions of endometrial cancer identified biomarkers associated with lymph node metastasis"}]},{"@id":"https://cir.nii.ac.jp/crid/1390566775142434560","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Current Status and Future Prospects of Biomarker Strategy for Drug Development"},{"@language":"ja","@value":"医薬品開発におけるバイオマーカー戦略の現状と展望"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1038/ncponc1187"},{"@type":"CROSSREF","@value":"10.1007/s00432-010-0974-9_references_DOI_QhH0Clls86wkB8VKIgOzNiEhX8r"},{"@type":"CROSSREF","@value":"10.1093/jjco/hyz068_references_DOI_QhH0Clls86wkB8VKIgOzNiEhX8r"},{"@type":"CROSSREF","@value":"10.1007/s00535-010-0369-3_references_DOI_QhH0Clls86wkB8VKIgOzNiEhX8r"},{"@type":"CROSSREF","@value":"10.1038/s41598-017-14418-5_references_DOI_QhH0Clls86wkB8VKIgOzNiEhX8r"},{"@type":"CROSSREF","@value":"10.3999/jscpt.51.151_references_DOI_QhH0Clls86wkB8VKIgOzNiEhX8r"}]}